Murulentumab GM102: An Novel Agent in Clinical Progression Murulentamab GM102 represents an innovative strategy for addressing refractory multiple myeloma . This designed monoclonal protein specifically interacts BCMA receptor expressed on cancerous cells, inducing antibody-dependent cellular killing. Early trial findings indicate early